Tentando aprender a traduzir a partir dos exemplos de tradução humana.
A partir de tradutores profissionais, empresas, páginas da web e repositórios de traduções disponíveis gratuitamente
Ζ θαξθηλνγφλνο δξάζε ηεο docetaxel δελ έρεη κειεηεζεί.
the carcinogenic potential of docetaxel has not been studied.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Ζ γνλνηνμηθόηεηα ηεο ηεκνπνξθίλεο έρεη κειεηεζεί ζε πεξηνξηζκέλν βαζκό.
the genotoxicity of temoporfin has been investigated to a limited extent.
Última atualização: 2011-10-23
Frequência de uso: 1
Qualidade:
Aviso: esta concordância pode estar incorreta.
Exclua-a, se este for o caso.
Σν emtriva δελ έρεη κειεηεζεί ζε αζζελείο ειηθίαο πάλσ απφ 65.
emtriva has not been studied in patients over the age of 65.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Ζ θαξκαθνθηλεηηθή ηεο docetaxel έρεη κειεηεζεί ζε ελήιηθεο θαξθηλνπαζείο κεηά απφ ρνξήγεζε
the pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Ηλικιυμένοι: Σν emtriva δελ έρεη κειεηεζεί ζε αζζελείο ειηθίαο πάλσ απφ 65.
elderly: emtriva has not been studied in patients over the age of 65.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Αιιειεπίδξαζε ηνπ mirabegron κε γλσζηφ αλαζηνιέα ηνπ cyp2d6 δελ αλακέλεηαη θαη δελ έρεη κειεηεζεί.
interaction of mirabegron with a known cyp2d6 inhibitor is not expected and was not studied.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Ζ θαξκαθνθηλεηηθή ηεο emtricitabine δελ έρεη κειεηεζεί ζε αζζελείο ρσξίο hbv ινίκσμε θαη πνηθίιινληεο βαζκνχο επαηηθήο αλεπάξθεηαο.
the pharmacokinetics of emtricitabine have not been studied in non-hbv infected subjects with varying degrees of hepatic insufficiency.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Σν sprimeo έρεη κειεηεζεί ζε 1.864 αζζελείο ειηθίαο 65 εηώλ θαη άλσ, θαζώο θαη ζε 426 αζζελείο ειηθίαο 75 εηώλ θαη άλσ.
sprimeo has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 75 years or older.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Σν mirabegron δελ έρεη κειεηεζεί ζε αζζελείο κε ζνβαξή επαηηθή δπζιεηηνπξγία (child- pugh θαηεγνξία Γ).
mirabegron has not been studied in patients with severe hepatic impairment (child-pugh class c).
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Αζζελείο κε λεθξηθή λφζν ηειηθνχ ζηαδίνπ νη νπνίνη ειέγρνληαη κε άιιεο κνξθέο θάζαξζεο, φπσο ε πεξηπαηεηηθή πεξηηνλατθή θάζαξζε, δελ έρνπλ κειεηεζεί θαη δελ κπνξνχλ λα γίλνπλ δνζνινγηθέο ζπζηάζεηο.
patients with end-stage renal disease (esrd) managed with other forms of dialysis such as ambulatory peritoneal dialysis have not been studied and no dose recommendations can be made.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Σν betmiga δελ έρεη κειεηεζεί ζε αζζελείο κε ζνβαξή επαηηθή δπζιεηηνπξγία (child-pugh Καηεγνξία Γ) θαη ζπλεπψο δε ζπληζηάηαη γηα ρξήζε ζε απηφλ ηνλ πιεζπζκφ αζζελψλ.
betmiga has not been studied in patients with severe hepatic impairment (child-pugh class c) and, therefore, it is not recommended for use in this patient population.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
ε θιηληθέο κειέηεο ην sprimeo δελ έρεη κειεηεζεί ζε ππεξηαζηθνύο αζζελείο κε ζνβαξή λεθξηθή δπζιεηηνπξγία (θξεαηηλίλε νξνύ ≥ 150 κmol/l ή 1,70 mg/dl ζε γπλαίθεο θαη ≥ 177 κmol/l ή 2,00 mg/dl ζε άληξεο θαη/ή εθηηκώκελν gfr < 30 ml/min/1,73 m2), κε ηζηνξηθό λεθξηθήο θάζαξζεο, λεθξσζηθνύ ζπλδξόκνπ ή λεθξαγγεηαθήο ππέξηαζεο.
in clinical studies sprimeo has not been investigated in hypertensive patients with severe renal impairment (serum creatinine ≥ 150 μmol/l or 1.70 mg/dl in women and ≥ 177 μmol/l or 2.00 mg/dl in men and/or estimated gfr < 30 ml/min/1.73 m2), history of dialysis, nephrotic syndrome or renovascular hypertension.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
Aviso: contém formatação HTML invisível